Sharon Wilks joins NEXT Oncology’s phase I clinical investigation team

Of adaptive and factorial designs
A biostatistician’s interpretation of last week’s ODAC

At its most recent meeting, the FDA Oncologic Drugs Advisory Committee focused on perioperative clinical trials, which the agency defined as neoadjuvant phase followed by surgery and continuing with adjuvant treatment using the same experimental agent (The Cancer Letter, July 26, 2024).

LifeCare Alliance, Ohio State collaborate to advance cancer health equity

LifeCare Alliance and the Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Center and Richard J. Solove Research Institute announced a partnership aimed at enhancing access to breast cancer screening and diagnostics for underserved individuals across Ohio.

August 02, 2024

Vol.50 No.31

Clinical Roundup

Language barriers hinder diverse recruitment to clinical trials

Underrepresentation of racial and ethnic minority populations in cancer clinical trials persists partly because translation and interpretation services and resources are unavailable or inadequate in the United States, according to a Children’s Oncology Group study led by Columbia University School of Nursing.

August 02, 2024

Vol.50 No.31

Regulatory News

ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications

The FDA Oncologic Drugs Advisory Committee July 25 voted unanimously to set more rigorous standards for new trials for approval of perioperative indications of cancer drugs.

July 26, 2024

Vol.50 No.30

By Jacquelyn Cobb and Paul Goldberg

Clinical Roundup

Electronic prompt for surgeons may reduce breast cancer overtreatment

University of Pittsburgh and UPMC Hillman Cancer Center researchers have developed a novel prompt, or ‘nudge,’ embedded in the electronic health record that flags, for treating surgeons, older patients with early-stage breast cancer who may be at risk for unnecessary lymph node surgery.

July 19, 2024

Vol.50 No.29

In Brief

Mark Burkard named director of UI Health Care Holden Comprehensive Cancer Center

Mark Burkard was named director of University of Iowa Health Care Holden Comprehensive Cancer Center.

July 12, 2024

Vol.50 No.28

Sharon Wilks joins NEXT Oncology’s phase I clinical investigation team

YOU MAY BE INTERESTED IN

Of adaptive and factorial designs
A biostatistician’s interpretation of last week’s ODAC

LifeCare Alliance, Ohio State collaborate to advance cancer health equity

Language barriers hinder diverse recruitment to clinical trials

ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications

Electronic prompt for surgeons may reduce breast cancer overtreatment

Mark Burkard named director of UI Health Care Holden Comprehensive Cancer Center

Renew today!

Subscriber content

Login

Sharon Wilks joins NEXT Oncology’s phase I clinical investigation team

YOU MAY BE INTERESTED IN

Of adaptive and factorial designsA biostatistician’s interpretation of last week’s ODAC

LifeCare Alliance, Ohio State collaborate to advance cancer health equity

Language barriers hinder diverse recruitment to clinical trials

ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications

Electronic prompt for surgeons may reduce breast cancer overtreatment

Mark Burkard named director of UI Health Care Holden Comprehensive Cancer Center

Login

Of adaptive and factorial designs
A biostatistician’s interpretation of last week’s ODAC